SCD and liver cancer: Previous studies have shown that c‐Myc can interact with the promoter of SREBP1, resulting in the reprogramming of fatty acid metabolism in liver cancer cells.[14] Moreover, c‐Myc has been demonstrated to increase the synthesis of particular eicosanoids in lung cancer cells, promoting the progression of lung cancer.[24b] In B‐cell lymphoma cell lines, c‐Myc stimulates increases in the mRNA and protein levels of crucial lipid synthesis enzymes, including ACACA, FASN, and SCD1.